Beclometasone

How to order Beclometasone

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Beclometasone on Prescriptsy

Beclometasone is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Beclometasone dipropionate is an inhaled corticosteroid (ICS) used as a preventer medicine for the long-term management of asthma in adults and children.

It is one of the most widely prescribed inhaled corticosteroids in the United Kingdom and is recommended by NICE, the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN) as a first-line preventer inhaler for patients whose asthma is not adequately controlled with an as-needed reliever inhaler alone.

Beclometasone is also used in some formulations for chronic obstructive pulmonary disease (COPD) management.

Inhaled corticosteroids are the cornerstone of asthma management.

By reducing chronic airway inflammation, they prevent symptoms, improve lung function, reduce the frequency and severity of exacerbations, and lower the risk of asthma-related hospital admissions and deaths.

This page provides a comprehensive clinical guide to beclometasone: how it works, how to use it correctly, the differences between formulations, side effects, and how to obtain a prescription in the UK.

Important safety information about beclometasone

Beclometasone is a preventer inhaler and is designed for regular daily use. It is not a reliever and will not help during an acute asthma attack. Note the following key safety points before starting treatment.

• Always carry your short-acting reliever inhaler (such as salbutamol) separately. Use your reliever for immediate symptom relief when you experience wheezing, breathlessness, or chest tightness.
• Different beclometasone products (such as Clenil Modulite and Qvar) deliver different particle sizes and are not interchangeable at the same dose. Always check the brand name on your prescription and do not switch products without medical advice.
• Do not stop inhaled beclometasone suddenly. Discuss any planned changes with your GP or asthma nurse.
• Rinse your mouth with water after each inhalation to reduce the risk of oral thrush and hoarseness.

What is asthma and why is a preventer inhaler important

Asthma is a chronic inflammatory disease of the airways characterised by variable airflow obstruction, bronchial hyperresponsiveness, and recurrent episodes of wheezing, breathlessness, chest tightness, and coughing.

In the UK, asthma affects approximately 5.4 million people and is responsible for around 1,400 deaths annually.

Many of these deaths are considered preventable with optimal management, including regular use of preventer inhalers.

The underlying pathology involves chronic eosinophilic inflammation of the bronchial mucosa, with structural changes (airway remodelling) developing over time if inflammation is not controlled.

Airway smooth muscle contracts excessively in response to triggers such as allergens, respiratory infections, exercise, cold air, and air pollution, causing episodic narrowing.

Without regular anti-inflammatory treatment, this cycle of inflammation and bronchoconstriction becomes self-perpetuating and progressively more difficult to control.

Inhaled corticosteroids address the root cause of asthma by suppressing airway inflammation.

Unlike reliever inhalers (such as salbutamol), which provide rapid but temporary bronchodilation without addressing inflammation, preventer inhalers provide sustained improvement in airway function when used consistently.

NICE and BTS/SIGN guidelines recommend stepping up to a low-dose ICS when a patient uses their reliever more than twice per week, has symptoms on more than two occasions per week, or experiences night-time waking due to asthma.

How beclometasone works: mechanism of action

Beclometasone dipropionate is a prodrug. After inhalation and deposition in the airways, it is hydrolysed by lung esterases to its active metabolite, beclometasone-17-monopropionate (17-BMP).

17-BMP binds with high affinity to the intracellular glucocorticoid receptor, forming a complex that translocates to the cell nucleus and modulates gene transcription.

The anti-inflammatory effects include suppression of pro-inflammatory cytokines (IL-1, IL-4, IL-5, IL-6, IL-13, TNF-alpha, and GM-CSF), reduction of eosinophil recruitment and survival, stabilisation of endothelial and epithelial cell barriers (reducing oedema and mucus leak), decreased mucus gland hyperplasia and mucus hypersecretion, restoration of beta-2 adrenoceptor responsiveness (improving the effectiveness of reliever inhalers), and reduction of airway smooth muscle hyperresponsiveness.

These changes do not occur immediately.

It typically takes 3 to 7 days of regular twice-daily use before noticeable clinical improvement, and the maximum anti-inflammatory effect may not be reached for 2 to 4 weeks.

This is why beclometasone must be taken every day as prescribed, even when symptoms are absent.

Beclometasone formulations available in the UK

Two principal formulation categories of inhaled beclometasone are available in the UK, and understanding the difference is clinically important because they are not dose-equivalent.

Standard particle (conventional) formulations

Clenil Modulite is the most commonly prescribed standard-particle beclometasone inhaler in the UK.

It delivers a CFC-free aerosol with a mass median aerodynamic diameter (MMAD) of approximately 2.9 micrometres. Available strengths include 50, 100, 200, and 250 micrograms per actuation.

The typical adult starting dose is 200 micrograms twice daily, adjustable up to 1000 micrograms daily in two divided doses for more severe asthma.

Extrafine particle formulations

Qvar (and Kelhale) deliver an extrafine aerosol with an MMAD of approximately 1.1 micrometres.

The smaller particle size achieves greater peripheral lung deposition (approximately 50 to 60% of the emitted dose, compared with 10 to 20% for standard formulations).

This means the prescribed dose is lower: a patient on Clenil 200 micrograms twice daily would typically require Qvar 100 micrograms twice daily to achieve equivalent clinical effect.

Your prescriber will calculate the appropriate dose when switching formulations.

Dry powder inhalers

Beclometasone is also available in dry powder inhaler (DPI) devices such as the Easyhaler.

DPIs are breath-actuated, meaning the dose is released by the force of the patient's inhalation rather than by pressing a canister.

DPIs do not require coordination of breathing and pressing and do not need a spacer.

They are an option for patients who find metered-dose inhalers difficult to use correctly.

Dosage and administration

The dose of beclometasone is individualised based on asthma severity, the specific inhaler product, and the patient's treatment response.

As a general guide, the BTS/SIGN stepwise approach categorises ICS doses as follows for adults using standard-particle beclometasone: low dose (200 to 400 micrograms daily), moderate dose (400 to 800 micrograms daily), and high dose (800 micrograms or more daily, up to a maximum of 2000 micrograms daily).

For extrafine formulations, the thresholds are approximately half these values.

The usual regimen is twice daily (morning and evening), though some products may be prescribed once daily at the discretion of the clinician.

Consistency of timing is more important than the specific time of day. Beclometasone should be used every day without interruption, including during symptom-free periods.

Discontinuation should be discussed with your GP or asthma nurse and, if appropriate, managed as a gradual dose reduction with monitoring.

Correct inhaler technique

The effectiveness of inhaled beclometasone depends critically on correct inhaler technique. Poor technique is one of the most common causes of inadequate asthma control.

For metered-dose inhalers (pMDIs), the patient should remove the cap, shake the inhaler, breathe out gently, place the mouthpiece between the lips, press the canister while breathing in slowly and deeply, hold the breath for 10 seconds, then breathe out slowly.

A spacer device significantly improves lung deposition and is recommended for most patients, especially children.

For dry powder inhalers, the patient should load the dose according to the device instructions, breathe out away from the device, then inhale forcefully and deeply through the mouthpiece.

After using any beclometasone inhaler, rinse your mouth with water and spit out.

Side effects of inhaled beclometasone

Common local side effects

Oropharyngeal candidiasis (oral thrush) is the most common side effect, occurring in up to 10% of patients.

It presents as white patches or plaques on the tongue, inner cheeks, palate, or throat, sometimes with soreness, altered taste, or difficulty swallowing.

Treatment is with topical antifungal agents (miconazole oral gel or nystatin suspension). Prevention is by mouth rinsing after each inhalation and spacer use.

Dysphonia (hoarseness or voice changes) affects approximately 5 to 10% of patients and results from corticosteroid-induced myopathy of the laryngeal muscles.

It is more common at higher doses and typically reversible with dose reduction or temporary discontinuation.

Systemic side effects

At low to moderate doses, systemic absorption of inhaled beclometasone is minimal and systemic side effects are uncommon.

At higher doses used long-term, potential systemic effects include adrenal suppression (reduced cortisol production, which can impair the body's stress response), reduced bone mineral density (with increased fracture risk over years of exposure), skin thinning and easy bruising, posterior subcapsular cataracts and glaucoma (with prolonged high-dose use), and in children, a small reduction in linear growth velocity, typically less than 0.5 to 1 cm in the first year of treatment, with evidence suggesting that final adult height is not significantly affected.

The risk of systemic effects is minimised by using the lowest dose that maintains asthma control, using a spacer device with pMDIs, and rinsing the mouth after each use.

Paradoxical bronchospasm

Rarely, inhaled beclometasone may cause paradoxical bronchospasm, characterised by an immediate increase in wheezing and breathlessness after inhalation.

If this occurs, use your reliever inhaler immediately and discontinue the beclometasone inhaler. Contact your GP for reassessment and consideration of an alternative ICS or delivery device.

Asthma management in the UK: the stepwise approach

BTS/SIGN and NICE recommend a stepwise approach to asthma management in which treatment is escalated or de-escalated based on symptom control and risk of exacerbation. Beclometasone features prominently in this framework.

• Step 1: As-needed short-acting beta-2 agonist (SABA) reliever only. Suitable for patients with infrequent, mild symptoms.
• Step 2: Add low-dose ICS (such as beclometasone 200 to 400 micrograms daily for standard particle, or equivalent). This is the first step at which regular preventer therapy is introduced.
• Step 3: If control is inadequate on low-dose ICS alone, options include adding a long-acting beta-2 agonist (LABA) as a combination inhaler with the ICS, or increasing the ICS dose to the moderate range.
• Steps 4 and 5: Higher-dose ICS, additional controller therapies (leukotriene receptor antagonists, long-acting muscarinic antagonists, theophylline), and specialist referral for biologic therapies.

Regular structured asthma reviews (at least annually, and after any exacerbation) are essential.

Reviews should assess symptom control, inhaler technique, adherence, trigger avoidance, and the ongoing appropriateness of the prescribed treatment step.

An asthma action plan should be provided to every patient.

How to get a beclometasone prescription in the UK

Beclometasone inhalers are prescription-only medicines (POM) in the UK.

The most common route is through your GP or asthma nurse, who will assess your symptoms, perform spirometry or peak flow testing if indicated, review your current treatment, and prescribe the most appropriate product and dose.

Repeat prescriptions are typically managed through your GP practice.

Authorised online prescribers registered with the GPhC can also prescribe beclometasone following a structured clinical consultation, provided that the patient's asthma diagnosis has been confirmed and appropriate monitoring is in place.

All UK prescriptions are dispensed by registered pharmacies.

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Patients who use multiple inhalers may benefit from a prepayment certificate (PPC).

Environmental considerations

Pressurised metered-dose inhalers (pMDIs) contain hydrofluoroalkane (HFA) propellants, which are potent greenhouse gases. A single salbutamol pMDI has a carbon footprint equivalent to approximately 28 kg of CO2.

Dry powder inhalers (DPIs) do not use propellants and have a significantly lower carbon footprint.

NHS England's Delivering a Net Zero NHS programme encourages switching to lower-carbon inhalers where clinically appropriate.

If you are interested in reducing the environmental impact of your inhaler, discuss DPI options with your GP or asthma nurse.

Any switch must be clinically appropriate and should not compromise asthma control.

When to seek urgent medical advice

Your preventer inhaler is one part of a broader asthma management plan.

Seek medical advice if you are using your reliever inhaler more than twice a week, if asthma symptoms are waking you at night, if you have had an exacerbation requiring oral corticosteroids or hospital attendance, or if your peak flow readings are consistently below your personal best.

Call 999 or attend A&E if you experience a severe asthma attack: extreme breathlessness that prevents speaking in full sentences, rapid breathing, a fast heartbeat, drowsiness or confusion, or blue discoloration of the lips or fingertips.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Clenil Modulite 200 micrograms, Summary of Product Characteristics (EMC)
• Qvar 100 Inhaler, Summary of Product Characteristics (EMC)
• Beclometasone dipropionate, British National Formulary (BNF)
• NICE NG80: Asthma: diagnosis, monitoring and chronic asthma management
• BTS/SIGN Guideline on the management of asthma
• Asthma, NHS
• MHRA Yellow Card Scheme